Fulvestrant: Treatment of Breast Cancer Antiestrogen

Drugs of the Future

Volumn 26, Issue 9, 2001, Pages 841-850

  Levin, Mark ^a   D'Souza, Nina ^a   Castaner J ^b,c  

^a LINCOLN MEDICAL AND MENTAL HEALTH CENTER   (United States)

^b PROUS SCIENCE   (Spain)

^c Mark Levin   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000915093     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.09.634749     Document Type: Article

References (33)

1. Bowler, J., Tait, B.T. (AstraZeneca plc). Steroid derivs. EP 0138504, US 4659516, JP 1985097995.
2. National Cancer Institute Cancernet. PDQ Treatment Statement for Health Professions, September 1999.
3. Honig, S.F. In: Diseases of the Breast, J.R. Harris, M.E. Lippman, M. Morrow, H. and H. Hellman (Eds.), Lippincott-Raven, 1996, 669.
4. Beatson, G.T. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative notes. Lancet 1896, 2: 104-7.
5. Nabholtz, J.M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., Steinberg, M., Webster, A., von Euler, M. Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000, 18: 3758-67.
6. Gallagher, A., Chambers, T.J., Tobias, J.H. The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats. Endocrinology 1993, 133: 2787-91.
7. Howell, A., Osborne, C.K., Morris, C., Wakeling, A.E. ICI 182,780 (Faslodex): Development of a novel, "pure" antiestrogen. Cancer 2000, 89: 817-25.
8. Carroll, J.S., Prall, O.W., Musgrove, E.A., Sutherland, R.L. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J Biol Chem 2000, 275: 38221-9.
9. Nicholson, R.I., Francis, R.B. et al. Pure anti-oestrogens (ICI 164384 and ICI 182780) and breast cancer: Is the attainment of complete oestrogen withdrawal worthwhile? Endocr-Relat Cancer 1994, 1: 5-17.
10. Cicatiello, L., Addeo, R., Altucci, L. et al. The antiestrogen ICI 182,780 inhibits proliferation of human breast cancer cells by interfering with multiple, sequential estrogen-regulated processes required for cell cycle completion. Mol Cell Endocrinol 2000, 165: 199-209.
11. Diel, P., Smolnikar, K., Michna, H. The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells. Breast Cancer Res Treat 1999, 58: 87-97.
12. Smolnikar, K., Loffek, S., Schulz, T., Michna, H., Diel, P. Treatment with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells. Breast Cancer Res Treat 2000, 63: 249-59.
13. Ferlini, C., DiStefano, M., Marone, M. et al. The synergistic anti-tumour activity of ICI 182,780 in combination with docetaxel is mediated by P-glycoprotein inhibition. Endocr-Relat Cancer 1998, 5: 315-24.
14. Rosenberg Zand, R.S., Grass, L., Magklara, A., Jenkins, D.J., Diamandis, E.P. Is ICI 182,780 an antiprogestin in addition to being an antiestrogen? Breast Cancer Res Treat 2000, 60: 1-8.
15. Nawaz, Z., Stancel, G.M., Hyder, S.M. The pure antiestrogen ICI 182,780 inhibits progestin-induced transcription. Cancer Res 1999, 59: 372-6.
16. Bouker, K.B., Skaar, T.C., Clarke, R. Interferon regulatory factor-1: A putative mediator of anti-estrogen responsiveness in breast cancer. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 16-19, Washington) 1999, Abst 237.
17. Osborne, C.K., Coronado-Heinsohn, E.B., Hilsenbeck, S.G., McCue, B.L., Wakeling, A.E., McClelland, R.A., Manning, D.L., Nicholson, R.I. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995, 87: 746-50.
18. Lee, E.S., Schafer, J.M., Yao, K., England, G., O'Regan, R.M., De Los Reyes, A., Jordan, V.C. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 2000, 6: 4893-9.
19. Hu, X.F., Veroni, M., De Luise, M., Wakeling, A., Sutherland, R., Watts, C.K., Zalcberg, J.R. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int J Cancer 1993, 55: 873-6.
20. Larsen, S.S., Madsen, M.W., Jensen, B.L., Lykkesfeldt, A.E. Resistance of human breast-cancer cells to the pure steroidal anti-estrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness. Int J Cancer 1997, 72: 1129-36.
21. Brunner, N., Boysen, B., Jirus, S., Skaar, T.C., Holst-Hansen, C., Lippman, J., Frandsen, T., Spang-Thomsen, M., Fuqua, S.A., Clarke, R. MCF7/LCC9: An antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res 1997, 57: 3486-93.
22. Parisot, J.P., Hu, X.F., Sutherland, R.L., Wakeling, A., Zalcberg, J.R., DeLuise, M. The pure antiestrogen ICI 182,780 binds to a high-affinity site distinct from the estrogen receptor. Int J Cancer 1995, 62: 480-4.
23. Lee, E.S., Horiguchi, J., Liu, H. Regulation of angiogenesis in tamoxifen-stimulated breast tumors by the pure antiestrogen ICI 182,780. Proc Amer Assoc Cancer Res 2000, 41: Abst 166.
24. Robertson, J.F.R. A comparison of the single-dose pharmacokinetics (PK) of "Faslodex" (fulvestrant) 250 mg when given as either a one × 5 ml intra-muscular (i.m.) injection or two × 2.5-ml injections in postmenopausal (PM) women with advanced breast cancer (ABC). 23rd Annu San Antonio Breast Cancer Symp (Dec 6-9, San Antonio) 2000, Abst 172.
25. DeFriend, D.J., Howell, A., Nicholson, R.I. et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994, 54: 408-14.
26. Thomas, E.J., Walton, P.L., Thomas, N.M., Dowsett, M. The effects of ICI 182,780, a pure anti-oestrogen, on the hypothalamic-pituitary-gonadal axis and on endometrial proliferation in pre-menopausal women. Hum Reprod 1994, 9: 1991-6.
27. Sibonga, J.D., Dobnig, H., Harden, R.M., Turner, R.T. Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia. Endocrinology 1998, 139: 3736-42.
28. Howell, A., DeFriend, D.J., Robertson, J.F., Blarney, R.W., Anderson, L., Anderson, E., Sutcliffe, F.A., Walton, P. Pharmacokinetics, pharmacological and anti tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 1996, 74: 300-8.
29. Howell, A. Pure antiestrogens. 2nd Breast Cancer Int Res Group (BCIRG) Conf (Toronto, June 26-28), 2000: Abst.
30. Osborne, C.K. A double-blind randomized trial comparing the efficacy and tolerability of Faslodex™ (fulvestrant) with Arimidex™ (anastrozole) in post-menopausal (PM) women with advanced breast cancer (ABC). 23rd Annu San Antonio Breast Cancer Symp (Dec 6-9, San Antonio) 2000, Abst 7.
31. Howell, A., Robertson, J.F.R., Quaresma Albano, J. et al. Comparison of efficacy and tolerability of fulvestrant (Faslodex™) with anastrozole (Arimidex™) in post-menopausal (PM) women with advanced breast cancer (ABC) - Preliminary results. 23rd Annu San Antonio Breast Cancer Symp (Dec 6-9, San Antonio) 2000, Abst 6.
32. Carlson, R.H. Fulvestrant and anastrozole found equally effective for tamoxifen resistant advanced breast cancer in post-menopausal patients. Oncol Times Meeting Report, March 2001.
33. AstraZeneca seeks FDA approval for breast cancer treatment. DailyDrugNews.com (Daily Essentials) April 2, 1001.